Amphastar Pharmaceuticals Inc

For the period ended Dec 31, 2024. Filed Mar 3, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 3, 2025

AMPH$29.38+3.1%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

(in thousands, except share data)


· December 31, · December 31,
· · 2024 · · 2023
ASSETS
Current assets:
Cash and cash equivalents	$151,609	$144,296
Restricted cash	235	235
Short-term investments	70,036	112,510
Restricted short-term investments	2,200	2,200
Accounts receivable, net	136,289	114,943
Inventories	153,741	105,833
Income tax refunds and deposits	1,747	526
Prepaid expenses and other assets	18,214	9,057
Total current assets	534,071	489,600

Property, plant, and equipment, net	297,345	282,746
Finance lease right-of-use assets	383	564
Operating lease right-of-use assets	46,899	32,333
Investment in unconsolidated affiliate	—	527
Goodwill and intangible assets, net	590,660	613,295
Long-term investments	10,996	14,685
Other assets	25,992	25,910
Deferred tax assets	71,124	53,252
Total assets	$1,577,470	$1,512,912

LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable and accrued liabilities	$157,057	$93,366
Accrued payments for BAQSIMI® (see Note 3)	—	126,090
Income taxes payable	9,664	1,609
Current portion of long-term debt	234	436
Current portion of operating lease liabilities	6,804	3,906
Total current liabilities	173,759	225,407

Long-term reserve for income tax liabilities	6,957	6,066
Long-term debt, net of current portion and unamortized debt issuance costs	601,630	589,579
Long-term operating lease liabilities, net of current portion	41,881	29,721
Other long-term liabilities	20,945	22,718
Total liabilities	845,172	873,491
Commitments and contingencies
Stockholders’ equity:
Preferred stock: par value $0.0001; 20,000,000 shares authorized; no shares issued and outstanding	—	—
Common stock: par value $0.0001; 300,000,000 shares authorized; 60,847,124 and 47,617,691 shares issued and outstanding, respectively, as of December 31, 2024 and 59,390,194 and 48,068,881 shares issued and outstanding, respectively, as of December 31, 2023	6	6
Additional paid-in capital	505,400	486,056
Retained earnings	568,787	409,268
Accumulated other comprehensive loss	(9,181)	(8,478)
Treasury stock	(332,714)	(247,431)
Total equity	732,298	639,421
Total liabilities and stockholders’ equity	$1,577,470	$1,512,912

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.